Introduction
Cytosor 100 mg (Cytarabine) Injection is a potent antimetabolite chemotherapy agent designed for the treatment of acute leukemias and leukemic meningitis. Manufactured by Eskayef Pharmaceuticals Ltd. and supplied globally by Onco Solution, Cytosor 100 mg (Cytarabine) Injection inhibits DNA synthesis, effectively targeting rapidly dividing cancer cells. With its proven efficacy and manageable safety profile, Cytosor 100 mg (Cytarabine) Injection is a cornerstone in modern oncology protocols.
Indications
Cytosor 100 mg (Cytarabine) Injection is indicated for:
- Leukemic Meningitis: Intrathecal administration for CNS involvement.
- Acute Leukemias: Induction and maintenance of remission in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Pharmacology
Cytosor 100 mg (Cytarabine) Injection exerts its cytotoxic effects by:
- Inhibiting DNA polymerase, preventing DNA synthesis and replication.
- Incorporating into DNA, leading to chain termination and cell death.
- Exhibiting antiviral and immunosuppressant activity.
Pharmacokinetics:
- Distribution: Rapidly distributed into tissues and cerebrospinal fluid (CSF).
- Metabolism: Primarily hepatic, converted to active and inactive metabolites.
- Excretion: Renal (70–80%) and biliary (10–20%).
Dosage & Administration
Cytosor 100 mg (Cytarabine) Injection is administered via intrathecal or intravenous routes under the supervision of an oncology specialist.
Recommended Dosage:
- Leukemic Meningitis (Intrathecal):
- 5–75 mg/m² or 30–100 mg once every 2–7 days for 4–5 days.
- For lymphomatous meningitis: 50 mg every 2 weeks for 5 doses, then every 4 weeks for 5 doses.
- Acute Leukemias (IV):
- Monotherapy: 200 mg/m² daily by continuous IV infusion for 5 days, repeated every 2 weeks.
- Combination Therapy: 100 mg/m² twice daily by rapid IV injection or 100 mg/m² daily by continuous IV infusion for 7 days.
- Maintenance Therapy: 1–1.5 mg/kg once or twice weekly via IV or SC.
